FOLH1 and prostate carcinoma: PSMA is virtually absent in most normal tissues, except for low-level expression in the salivary glands, kidneys, and small intestine, making it a highly specific target for prostate cancer imaging and therapy, as well as an ideal biomarker for radiolabeled treatments [9,10,11].